N/A N=197 Pancreaticobiliary Reflux in Patients Without Cholelithiasis
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position
Ureteral Obstruction
Primary: Incidence of Bladder Irritation Symptoms (e.g. Frequency, Urgency, Nocturia, Urine Leakage...) Associated With the RELIEF Stent. — 51.95 Units on a scale
N/A N=760 Observational Study of Anti-Reflux Surgery
GERD · Gastroesophageal Reflux · Gastro Esophageal Reflux
Primary: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) — 4.2; 4.9 score on a scale
N/A N=95 Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Laryngopharyngeal Reflux
Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
N/A N=68 Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
Gastroesophageal Reflux Disease (GERD)
Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002
Phase 2 N=27 TLESR-impedance Study in Patients
Reflux Episodes
Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters
Phase 4 N=506 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
Gastroesophageal Reflux
Primary: Change From Baseline in Reflux Disease Symptom - Heartburn — 59; 117; 186; 7 participants
N/A N=16 A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
Otitis Media With Effusion
Primary: Absence of Middle Ear Fluid by Pneumatic Otoscopy, Right Ear — 1; 0 participants
N/A N=63 Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
GERD
Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes
Phase 4 N=152 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
GERD Gastroesophageal Reflux Disease
Primary: Elimination of Moderate-severe Regurgitation at 6 Months — 10; 42 Participants
Phase 2 N=27 A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
Gastroesophageal Reflux Disease
Primary: Total Number of Reflux Episodes During 24 Hours — 59.4; 50.7; 44.3; 38.0 Episodes
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
N/A N=75 Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Gastro-esophageal Reflux Disease
Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change
N/A N=47 Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease
GERD · Larynx Disease
Primary: Decrease in pH From Baseline to <4 — 1.1; 3.2; 3.8 distal esophagus total % time pH <4 — p=.05
N/A N=65 Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002
N/A N=76 Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial
Gastroesophageal Reflux Disease
Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28
Phase 3 N=402 Study of Acid Reflux in Asthma
Asthma · Lung Diseases · Lung Diseases, Obstructive
Primary: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion — 2.3; 2.5 events per person…
Phase 4 N=276 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Gastroesophageal Reflux Disease
Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants
Phase 4 N=337 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
Phase 4 N=52 Role of Pepsin Assay in Wheezy Infants
Gastroesophageal Reflux Disease
Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants
Phase 3 N=366 A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
GERD
Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
Phase 2 N=480 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease
Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128
Phase 3 N=337 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…
Phase 2 N=17 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks
Phase 2 N=244 Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
Gastroesophageal Reflux Disease (GERD)
Primary: Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of…